<DOC>
	<DOCNO>NCT01531595</DOCNO>
	<brief_summary>- Open-label , single-arm , phase II study bevacizumab ( AvastinTM ) combination alternate Xeliri Xelox first-line treatment patient metastatic colorectal cancer . - Primary objective : PFS , To assess overall resectability patient metastatic colorectal cancer , postoperative morbidity outcomes resection . - Secondary objective : To assess response rate accord RECIST criterion , failure free survival ( TTF ) overall survival ( OS ) , Quality life accord 15D questionnaire , To radiologically assess tumour density morphology , assess alternative radiologic response evaluation comparison RECIST response criterion , Biomarker evaluation measure plasma biomarkers , tumour block DNA polymorphism may predict drug effect , safety , resectability clinical behaviour tumour</brief_summary>
	<brief_title>Study Bevacizumab Combination With Alternating Xeliri Xelox Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Patients histologically confirm diagnosis CRC , chemotherapy naïve metastatic disease ( prior adjuvant chemotherapy 6 month previously CRC allow ) , schedule start first line chemotherapy metastatic disease 2 . Age &gt; 18 3 . Measurable evaluable metastatic disease 4 . Performance status ECOG performance status 02 5 . Life expectancy great 3 month 6 . Normal Thrombocytes , neutrophil , Aspartate amino transferase/Alanine amino transferase , Alkaline phosphatase , Serum bilirubin , Serum Creatinine , Urine dipstick proteinuria . 7 . Women childbearing potential must negative serum pregnancy test do prior administration bevacizumab . Patient partner adequate contraception least 6 month last treatment completion last drug dose , whatever happen first 8 . Signed write informed consent accord ICH/GCP local regulation ( approved Independent Ethics Committee [ IEC ] ) obtain prior study specific screen procedure 9 . Patient must able comply protocol 1 . Prior treatment firstline chemotherapy metastatic CRC 2 . Adjuvant treatment within 6 month 3 . Major surgical procedure ( place central venous access device liver biopsy etc consider minor procedure ) , open biopsy significant traumatic injury within 28 day prior Day 0 ( Patients must recover major surgery ) 4 . Near future plan radiotherapy underlie disease ( prior complete radiotherapy treatment allow ) 5 . Clinical radiological evidence CNS metastases 6 . Past current history within last 2 year malignancy except indication study curatively treat basal squamous cell carcinoma skin insitu carcinoma cervix 7 . Serious nonhealing wound ulcer 8 . Evidence bleed diathesis coagulopathy 9 . Uncontrolled hypertension 10 . Clinically significant ( i.e . active ) cardiovascular disease example cerebrovascular accident ( ≤ 6 month ) , myocardial infarction ( ≤ 6 month ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication 11 . Treatment investigational drug within 30 day prior enrolment 12 . Evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate treatment patient high risk treatment complication 13 . Chronic daily intake aspirin ( &gt; 325 mg/day ) clopidogren ( &gt; 75 mg/day ) 14 . Pregnancy ( positive serum pregnancy test ) lactation 15 . Any serious uncontrolled illness , opinion investigator , make undesirable patient enter trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>